The importance of preserving renal function in patients with atrial fibrillation and diabetes

The Kidneys Matter in Patients with Atrial fibrillation and diabetes.



For full prescribing information, refer to the package insert approved by the Medicines Authority (SAHPRA).

XARELTO® 10 (Rivaroxaban 10 mg): South Africa:  S4  Reg. No.: 42/8.2/1046; Namibia:  NS2  10/8.2/0463; Botswana:  S2  BOT1302278; Zimbabwe: PP10 Reg. 2017/10.2/5362; Mauritius: R12697/02/14.

XARELTO® 15 (Rivaroxaban 15 mg): South Africa:  S4  Reg. No.: 46/8.2/0111; Namibia:  NS2  12/8.2/0006; Botswana:  S2  BOT1302278; Zimbabwe: PP10 Reg. 2017/10.2/5363; Mauritius: R11772/02/14.

XARELTO® 20 (Rivaroxaban 20 mg): South Africa:  S4  Reg. No.: 46/8.2/0112; Namibia:  NS2  12/8.2/0007; Botswana:  S2  BOT1302297; Zimbabwe: PP10 Reg. 2017/10.2/5364; Mauritius: R12698/02/14. 

Applicant/HCR: Bayer (Pty) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609.